0.05Open0.05Pre Close0 Volume11 Open Interest2.50Strike Price0.00Turnover672.78%IV129.73%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1713Delta0.3582Gamma22.20Leverage Ratio-0.0258Theta0.0000Rho3.80Eff Leverage0.0003Vega
Aslan Pharmaceuticals Stock Discussion
5 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE
ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company dedicated to developing innovative treatments for patients, has announced a significant late-breaking poster presentation at the American Thoracic Society (ATS) International Conference 2024 in San Diego, Californ...
•Late breaking poster presentation of positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of COPD at the American Thoracic Society International Conference 2024 on May 20, 2024 •Topline interim data from the farudodstat Phase 2a study in AA expected in Q3 2024•Topline data from the TREK-DX trial of eblasakimab expected at the end of 2024•Selection of a dev...
Hi @Trytosaveabit May i kindly get ur opinion/ analysis on this company (No advise on buy sell).
No comment yet